SCHEMBL5542340

SCHEMBL5542340

O=[C]CCN1CCN(C(=O)Nc2ccc(Cl)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 5/20 0.59
CA12 O43570 3/20 0.55
CA2 P00918 3/20 0.55
CA9 Q16790 3/20 0.55
CA1 P00915 2/20 0.55
ALOX5 P09917 1/20 0.54
USP2 O75604 1/20 0.53
LMNA P02545 3/20 0.52
MAPK1 P28482 2/20 0.52
GAA P10253 1/20 0.52
TRPV1 Q8NER1 1/20 0.52
TP53 P04637 2/20 0.52
MAPT P10636 1/20 0.52
CCR2 P41597 1/20 0.51
KCNH2 Q12809 1/20 0.51
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
KDM4E B2RXH2 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536453 0.86 KMT2A (0.58) FAAHCA12CA2CA9CA1
SCHEMBL5546588 0.86 NPC1 (0.58) FAAHCA12CA2CA9CA1
SCHEMBL5541733 0.86 FAAH (0.65) FAAHCA12CA2CA9MAPT
SCHEMBL13926082 0.85 FAAH (0.63) FAAHCA12CA2CA9CA1
SCHEMBL5544609 0.83 FAAH (0.60) FAAHLMNATRPV1MAPTCCR2
SCHEMBL5546036 0.83 MAPT (0.70) FAAHTP53MAPTCCR2SMN1; SMN2
SCHEMBL27979652 0.82 CA12 (0.71) FAAHCA12CA2CA9CA1
SCHEMBL5542346 0.81 FAAH (0.59) FAAHCA12CA2CA9CA1
SCHEMBL5541508 0.81 NPC1 (0.61) FAAHCA12CA2CA9CA1
SCHEMBL5535035 0.80 ACHE (0.66) LMNATRPV1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 FAAH 4363/4885CA12 1998/4885CA2 1853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.